Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novel Therapeutic Opportunities in Neoadjuvant Setting in Urothelial Cancers: A New Horizon Opened by Molecular Classification and Immune Checkpoint Inhibitors
Maria Lucia Iacovino, Chiara Carmen Miceli, Marco De Felice, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1133-1133
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review
Biagio Barone, Armando Calogero, Luca Scafuri, et al.
Cancers (2022) Vol. 14, Iss. 10, pp. 2545-2545
Open Access | Times Cited: 52
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer
Nicola Antonio di Meo, Davide Loizzo, Savio Domenico Pandolfo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4173-4173
Open Access | Times Cited: 51
Immunotherapy for Bladder Cancer: Latest Advances and Ongoing Clinical Trials
Daniela F. Ward Grados, Hamed Ahmadi, Thomas S. Griffith, et al.
Immunological Investigations (2022) Vol. 51, Iss. 8, pp. 2226-2251
Open Access | Times Cited: 28
Epigenetic and Immunological Features of Bladder Cancer
I. R. Gilyazova, Kadriia Enikeeva, Guzel Rafikova, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9854-9854
Open Access | Times Cited: 15
Efficacy of immune checkpoint inhibitors combinations as first-line systemic treatment in patients with advanced urothelial carcinoma: A systematic review and network meta-analysis
Fernando Sabino Marques Monteiro, Andrey Soares, Veronica Mollica, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104321-104321
Closed Access | Times Cited: 5
An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer
Michail Sarafidis, George Ι. Lambrou, Vassilis Zoumpourlis, et al.
Cancers (2022) Vol. 14, Iss. 14, pp. 3358-3358
Open Access | Times Cited: 17
Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis
Canling Lin, Jiajun Cui, Zhen Peng, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 15
Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review
Gongwei Long, Siquan Ma, Runlin Shi, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 866-866
Open Access | Times Cited: 12
LPCAT1 acts as an independent prognostic biomarker correlated with immune infiltration in hepatocellular carcinoma
Lan Li, Xiao Wang, Yanni Ding, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 11
Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Matteo Ferro, Felice Crocetto, Octavian Sabin Tătaru, et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 5, pp. 574-583
Closed Access | Times Cited: 5
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Seema Mustafa, Caroline S. Jansen, Yash Jani, et al.
Biomarker Insights (2024) Vol. 19
Open Access | Times Cited: 1
Neoadjuvant Chemotherapy before Nephroureterectomy in High-Risk Upper Tract Urothelial Cancer: A Systematic Review and Meta-Analysis
David Oswald, Maximilian Pallauf, Susanne Deininger, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4841-4841
Open Access | Times Cited: 8
Understanding Treatment Patterns and Outcomes among Patients with De Novo Unresectable Locally Advanced or Metastatic Urothelial Cancer: A Population-Level Retrospective Analysis from Alberta, Canada
Nimira Alimohamed, Simrun Grewal, Heidi S. Wirtz, et al.
Current Oncology (2022) Vol. 29, Iss. 10, pp. 7587-7597
Open Access | Times Cited: 8
A model for predicting overall survival in bladder cancer patients with signet ring cell carcinoma: a population-based study
Liang Liu, Chuangui Li, Qiang Wang, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 4
Diminishing the Gender-Related Disparity in Survival among Chemotherapy Pre-Treated Patients after Radical Cystectomy—A Multicenter Observational Study
Krystian Kaczmarek, Artur Lemiński, Bartosz Małkiewicz, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1260-1260
Open Access | Times Cited: 4
LRRC59 serves as a novel biomarker for predicting the progression and prognosis of bladder cancer
Peng Zhang, Xiaodu Xie, Chunming Li, et al.
Cancer Medicine (2023) Vol. 12, Iss. 19, pp. 19758-19776
Open Access | Times Cited: 4
Systematic oxidative stress indices predicts prognosis in patients with urothelial carcinoma of the upper urinary tract after radical nephroureterectomy
Jianyong Liu, Shicong Lai, Pengjie Wu, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 4
Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma
Gavin Hui, Dimitrios Stefanoudakis, Yuliya Zektser, et al.
Current Oncology (2023) Vol. 30, Iss. 8, pp. 7398-7411
Open Access | Times Cited: 3
Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer
Josep Sabaté Ortega, Roser Fort Culillas, Marina Escoda Garcia, et al.
Current Oncology (2023) Vol. 30, Iss. 9, pp. 7802-7809
Open Access | Times Cited: 3
Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes
Krystian Kaczmarek, Bartosz Małkiewicz, Karolina Skonieczna‐Żydecka, et al.
Cancers (2023) Vol. 15, Iss. 19, pp. 4901-4901
Open Access | Times Cited: 3
Nature’s Hidden Gem: quercitrin’s Promising Role in Preventing Prostate and Bladder Cancer
Benito Fabio Mirto, Luca Scafuri, Enrico Sicignano, et al.
Future Science OA (2023) Vol. 9, Iss. 6
Open Access | Times Cited: 2
Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis
Yixin Zhou, Qiancheng Hu, Yajuan Zhu, et al.
European journal of medical research (2023) Vol. 28, Iss. 1
Open Access | Times Cited: 2
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
Luca Filippi, Orazio Schillaci
Expert Review of Anticancer Therapy (2023) Vol. 24, Iss. 1-2, pp. 1-4
Closed Access | Times Cited: 2
Deciphering the significance of anoikis in bladder cancer and systematic analysis of S100A7 as a potential therapeutic target
Haoran Wang, Jianyong Liu, Runhua Tang, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access
The association between paraneoplastic neurological syndromes (PNS) and urothelial carcinoma – A review of the literature
Sarafina Urenna Otis, Giuseppe Luigi Banna, Akash Maniam
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104314-104314
Closed Access
Page 1 - Next Page

Scroll to top